Home › Type 2 Diabetes › NCT06593327
NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
Evaluation of a Pragmatic NT-ProBNP-based Heart Failure Screening Strategy Among Patients With Type 2 Diabetes: STRONG-DM Study (Screening and Treatment Using Risk-based apprOach With NT-ProBNP Guidance in Diabetes Mellitus
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Primary Care Provider that sees diabetes patients in clinic Exclusion Criteria: * Provider does not see patients with Diabetes
About the study
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strategy among patients with high risk focused on implementation of evidence-based HF preventive therapies.
What is being tested
- Intensive Prevention Strategy (behavioral)
Sponsor: University of Texas Southwestern Medical Center · Participants: 300 · Started: Feb 10, 2025
Contact the study team
- Ambarish Pandey, MD · Phone: 617-869-8957
- VINAYAK SUBRAMANIAN, MD · Phone: 2114-645-9868
Official record on ClinicalTrials.gov — NCT06593327
Locations in the U.S.
| Texas | Baylor Scott and White - Health System, Dallas Parkland Health & Hospital System (PHHS), Dallas University of Texas Southwestern Medical Center, Dallas |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.